CDK12 and neoplasm: In metastatic prostate cancer displaying transcriptional addiction, it can be envisaged that treatment with a combination of CDK7, CDK9, and/or CDK12/CDK13 inhibitors may lead to potent suppression of oncogenic transcription, since all of these tCDKs have established AR signalling and tumour-promoting roles in relevant disease models [55, 59, 61].